Market Cap : 8.15 B | Enterprise Value : 7.98 B | P/E (TTM) : | P/B : 47.94 |
---|
NAS:BBIO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:BBIO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, BridgeBio Pharma's enterprise value is $7,977.48 Mil. BridgeBio Pharma's EBITDA for the trailing twelve months (TTM) ended in Sep. 2020 was $-425.88 Mil. Therefore, BridgeBio Pharma's EV-to-EBITDA for today is -18.73.
During the past 3 years, the highest EV-to-EBITDA of BridgeBio Pharma was -7.00. The lowest was -19.30. And the median was -10.60.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2021-01-21), BridgeBio Pharma's stock price is $66.440000. BridgeBio Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2020 was $-3.41. Therefore, BridgeBio Pharma's PE Ratio for today is .
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.
* The bar in red indicates where BridgeBio Pharma's EV-to-EBITDA falls into.
BridgeBio Pharma's EV-to-EBITDA for today is calculated as:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA (TTM) |
= | 7977.480 | / | -425.881 | |
= | -18.73 |
BridgeBio Pharma's current Enterprise Value is $7,977.48 Mil.
BridgeBio Pharma's EBITDA for the trailing twelve months (TTM) ended in Sep. 2020 was -81.111 (Dec. 2019 ) + -100.072 (Mar. 2020 ) + -125.46 (Jun. 2020 ) + -119.238 (Sep. 2020 ) = $-425.88 Mil.
* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
BridgeBio Pharma's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 66.440000 | / | -3.41 | |
= |
BridgeBio Pharma's share price for today is $66.440000.
BridgeBio Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2020 was -0.62 (Dec. 2019 ) + -0.78 (Mar. 2020 ) + -1.03 (Jun. 2020 ) + -0.98 (Sep. 2020 ) = $-3.41.
* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Please read Which price ratio outperforms the enterprise multiple?
No Headline